If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 375.00
Bid: 370.00
Ask: 380.00
Change: 5.00 (1.37%)
Spread: 10.00 (2.703%)
Open: 365.00
High: 370.00
Low: 370.00
Prev. Close: 365.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options

10 Aug 2021 07:00

RNS Number : 0791I
MaxCyte, Inc.
10 August 2021
 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Grant of Options

Gaithersburg, Maryland - 10 August 2021: MaxCyte  (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, announces that on 9 August 2021, options of common stock in the Company ("Common Stock") were granted equally to all Company employees, including 100,000 options granted to PDMRs who are directors or officers of the Company ("PDMR Option Grants"). Details of the PDMR Option Grants are given below:

 

Grants to PDMRs

 

Doerfler, Doug

10,000

Thompson, J. Stark

10,000

Mandell, Art

10,000

Erck, Stan

10,000

Brooke, Will

10,000

Johnston, John

10,000

Douglas, Richard

10,000

Hemrajani, Rekha

10,000

Al-Wakeel, Yasir

10,000

Murphy, Amanda

10,000

Total

100,000

 

 

All option grants vest over 4 years. 1/4th of the grants vest 1 year following the date of the grant, with the remainder of the options vesting ratably monthly in 36 monthly installments thereafter. The options have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 9 August 2021, of $16.63

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Doug Doerfler

2

Reason for the notification

a)

Position/status

Chief Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

J. Stark Thompson

2

Reason for the notification

a)

Position/status

Chairman

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Art Mandell

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Stan Erck

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Will Brooke

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

John Johnston

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Douglas

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Rekha Hemrajani

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Yasir Al-Wakeel

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Amanda Murphy

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

MaxCyte Contacts:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Financial Officer

 

 

+1 301-944-1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

 

+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black / Duncan Monteith / Matthew O'Dowd

 

 

+44 (0)20 7260 1000

Joint Corporate Broker

Stifel Nicolaus Europe Limited

Healthcare Investment Banking

Nicholas Moore / Ben Maddison / Samira Essebiyea

Corporate Broking

Nick Adams

 

 

+44 (0)20 7710 7600

 

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

 

+44 (0)203 709 5700

maxcyte@consilium-comms.com

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

 

+1 415-937-5400

 ir@maxcyte.com

 

US Media Relations

Jamie Lacey-Moreira

PressComm PR, LLC

 

+1 410-299-3310

jamielacey@presscommpr.com

 

 

 

 

About MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies - including 20 of the top 25 pharmaceutical companies based on 2020 global revenue - to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAFPNELEFEAA
Date   Source Headline
8th May 20247:05 amRNSFiling of Form 10-Q
8th May 20247:00 amRNSFirst Quarter Results
3rd May 20247:00 amRNSNotice of AGM
1st May 20245:04 pmRNSTotal Voting Rights
10th Apr 20241:05 pmRNSNotice of Results
3rd Apr 20247:00 amRNSTotal Voting Rights and Block Listing Return
2nd Apr 20241:05 pmRNSSigning of Strategic Platform License
2nd Apr 20247:00 amRNSExercise of options and PDMR dealing
20th Mar 202410:16 amRNSGrant of Options, RSUs and PSUs and PDMR Dealing
20th Mar 202410:05 amRNSGrant of Options, RSUs and PSUs and PDMR Dealing
13th Mar 20247:05 amRNSFiling of form 10-K for FY ended December 31, 2023
13th Mar 20247:00 amRNSReports Q4 & FY 2023 Financial Results
6th Mar 20248:58 amRNSTR-1: Notification of major holdings
5th Mar 20247:00 amRNSPreliminary FY Results & 2024 Guidance
1st Mar 20245:57 pmRNSTotal Voting Rights
29th Feb 20249:21 amRNSExercise of options and PDMR dealing
26th Feb 20247:00 amRNSTR-1: Notification of major holdings
9th Feb 20241:05 pmRNSNotice of Results
1st Feb 20249:24 amRNSTotal Voting Rights
31st Jan 20247:00 amRNSDirector/PDMR Shareholding
30th Jan 20242:29 pmRNSHolding(s) in Company
30th Jan 20241:05 pmRNSSigning of Strategic Platform License
29th Jan 20244:52 pmRNSTR-1: Notification of major holdings
29th Jan 20247:00 amRNSFiling of Form 8-K
23rd Jan 20241:05 pmRNSSigning of Strategic Platform License
9th Jan 20247:00 amRNSPreliminary Unaudited Q4 and FY 2023 Results
5th Jan 20247:00 amRNSGrant of Options and PDMR Dealing
3rd Jan 20241:05 pmRNSSigning of Strategic Platform License
2nd Jan 20249:23 amRNSTotal Voting Rights
2nd Jan 20247:00 amRNSConfirmation of Board change
29th Dec 20237:00 amRNSExercise of options and PDMR dealing
12th Dec 20237:00 amRNSCEO Transition and Revenue Guidance Update
7th Dec 20239:50 amRNSExercise of options and PDMR dealing
4th Dec 20237:00 amRNSExercise of options and PDMR dealing
1st Dec 20235:43 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of options and PDMR dealing
17th Nov 20237:00 amRNSExercise of options and PDMR dealing
16th Nov 20231:05 pmRNSMaxCyte Joins the Alliance for mRNA Medicines
9th Nov 20237:01 amRNSFiling of Form 10-Q
9th Nov 20237:00 amRNSThird Quarter Results
7th Nov 20237:00 amRNSParticipation in Upcoming Investor Conferences
1st Nov 20231:12 pmRNSTotal Voting Rights
5th Oct 20237:00 amRNSPreliminary Q3 Revenue & FY Revenue Guidance
2nd Oct 20234:03 pmRNSTotal Voting Rights
13th Sep 20232:28 pmRNSTR-1: Notification of major holdings
12th Sep 20231:21 pmRNSTR-1: Notification of major holdings
5th Sep 20234:17 pmRNSTR-1: Notification of major holdings
5th Sep 20231:05 pmRNSBaird Global Healthcare Conference Participation
4th Sep 20231:32 pmRNSTR-1: Notification of major holdings
4th Sep 20237:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.